Study #2015-0555
A Phase 1, Dose-Finding Study of Folotyn? (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)
MD Anderson Study Status
Not Accepting
Treatment Agent
Pralatrexate Injection
Description
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
Information and next steps
Disease:
Peripheral T-Cell Lymphoma (PTCL)
Study phase:
I
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help us #endcancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.